Literature DB >> 11981616

Telomerase in brain tumors.

M L Falchetti1, L M Larocca, R Pallini.   

Abstract

INTRODUCTION: In recent years, many scientists involved in cancer research have directed their attention to telomerase, an enzymatic complex which is specifically involved in duplicating telomeres, the very ends of linear chromosomes. The discovery that most immortal cell lines in vitro and human tumor cells in vivo have telomerase activity, in contrast to telomerase-negative normal somatic cells, has made telomerase a candidate for use as a molecular marker of malignancy and even as a target for anticancer therapies. Thus, the assessment of the role of telomerase activity in neoplastic transformation has become a key issue in oncology, as stated by the exponential increase of papers on telomerase in the last 5 years. OBJECT: In this paper, we review some recent data from the literature, including our own studies, on the regulation of telomerase activity in brain tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981616     DOI: 10.1007/s00381-002-0562-7

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  15 in total

1.  Progression of astrocytomas and meningiomas: an evaluation in vitro.

Authors:  L Maes; J P O Kalala; M Cornelissen; L de Ridder
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.

Authors:  Sabine Spiegl-Kreinecker; Daniela Lötsch; Bahil Ghanim; Christine Pirker; Thomas Mohr; Magdalena Laaber; Serge Weis; Alfred Olschowski; Gerald Webersinke; Josef Pichler; Walter Berger
Journal:  Neuro Oncol       Date:  2015-02-13       Impact factor: 12.300

3.  Expression of telomeres in astrocytoma WHO grade 2 to 4: TERRA level correlates with telomere length, telomerase activity, and advanced clinical grade.

Authors:  Sandra Sampl; Sibylle Pramhas; Christian Stern; Matthias Preusser; Christine Marosi; Klaus Holzmann
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 4.  Ependymoma in children: molecular considerations and therapeutic insights.

Authors:  J-H Kim; Y Huang; A S Griffin; P Rajappa; J P Greenfield
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

5.  Telomere maintenance in childhood primitive neuroectodermal brain tumors.

Authors:  Domenico Didiano; Tarek Shalaby; Doris Lang; Michael A Grotzer
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

6.  hTERT gene amplification and increased mRNA expression in central nervous system embryonal tumors.

Authors:  Xing Fan; Yunyue Wang; John Kratz; Dan J Brat; Yves Robitaille; Albert Moghrabi; Elizabeth J Perlman; Chi V Dang; Peter C Burger; Charles G Eberhart
Journal:  Am J Pathol       Date:  2003-06       Impact factor: 4.307

7.  Tumor-specific activity of cellular regulatory elements is down-regulated upon insertion into the herpes simplex virus genome.

Authors:  Mandy Glass; Ariane Söling; Martin Messerle
Journal:  J Neurovirol       Date:  2008-11       Impact factor: 2.643

8.  The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth.

Authors:  Calin O Marian; Steve K Cho; Brian M McEllin; Elizabeth A Maher; Kimmo J Hatanpaa; Christopher J Madden; Bruce E Mickey; Woodring E Wright; Jerry W Shay; Robert M Bachoo
Journal:  Clin Cancer Res       Date:  2010-01-01       Impact factor: 12.531

9.  Association of telomerase gene hTERT polymorphism and malignant gliomas.

Authors:  Catherine Carpentier; Julie Lejeune; Florent Gros; Sibille Everhard; Yannick Marie; Gentian Kaloshi; Florence Laigle-Donadey; Khe Hoang-Xuan; Jean-Yves Delattre; Marc Sanson
Journal:  J Neurooncol       Date:  2007-04-05       Impact factor: 4.130

10.  Prognostic implication of telomerase activity in patients with brain tumors.

Authors:  Choong Hyun Kim; Jin Hwan Cheong; Koang Hum Bak; Jae Min Kim; Suck Jun Oh
Journal:  J Korean Med Sci       Date:  2006-02       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.